Literature DB >> 19291457

Methadone and methadone metabolites in postmortem specimens.

Terry J Danielson1, Ashraf Mozayani, Luis A Sanchez.   

Abstract

We have determined drug/metabolite concentrations and ratios of methadone (METH) to two of its metabolites (EDDP, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine; and EMDP, 2-ethyl-5-methyl-3,3-diphenylpyrroline) in postmortem peripheral blood and liver tissue by liquid chromatography/tandem mass spectrometry. The assays employed deuterated internal standards and multiple reaction monitoring (MRM) techniques. The assay linear range was 0.01-2.0 mg/l for each analyte. METH, EDDP, and EMDP were determined in liver and peripheral blood from 46 methadone-positive cases. METH and EDDP were detected in all specimens, whether blood or liver. EMDP was detected, only in liver, and only 17 cases, at concentrations much lower than those of EDDP. Concentrations of METH and EDDP in blood and liver from EMDP-positive cases were in ranges higher than, but overlapping with, concentrations in blood and liver from EMDP-negative cases. These data suggest that although METH is readily demethylated and cyclized to EDDP, in vivo, conversion to EMDP may be less efficient and its accumulation in postmortem tissues may be highly individual.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19291457     DOI: 10.1007/s12024-008-9039-7

Source DB:  PubMed          Journal:  Forensic Sci Med Pathol        ISSN: 1547-769X            Impact factor:   2.007


  18 in total

1.  Cytochrome P450 2D6 genotype and methadone steady-state concentrations.

Authors:  C B Eap; F Broly; A Mino; R Hämmig; J J Déglon; C Uehlinger; D Meili; A F Chevalley; G Bertschy; D Zullino; M Kosel; M Preisig; P Baumann
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

2.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

3.  Enantiomeric metabolic interactions and stereoselective human methadone metabolism.

Authors:  Rheem A Totah; Kyle E Allen; Pamela Sheffels; Dale Whittington; Evan D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  2007-01-26       Impact factor: 4.030

4.  Methadone deaths: a toxicological analysis.

Authors:  C M Milroy; A R Forrest
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

5.  Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.

Authors:  Stefan Begré; Ulrich von Bardeleben; Dieter Ladewig; Sylvie Jaquet-Rochat; Line Cosendai-Savary; Kerry Powell Golay; Markus Kosel; Pierre Baumann; Chin B Eap
Journal:  J Clin Psychopharmacol       Date:  2002-04       Impact factor: 3.153

6.  Urinary metabolites of dl-methadone in maintenance subjects.

Authors:  H R Sullivan; S L Due
Journal:  J Med Chem       Date:  1973-08       Impact factor: 7.446

7.  Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat.

Authors:  A Pohland; H E Boaz; H R Sullivan
Journal:  J Med Chem       Date:  1971-03       Impact factor: 7.446

8.  Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry.

Authors:  Robin E Choo; Constance M Murphy; Hendrée E Jones; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-01-25       Impact factor: 3.205

9.  Plasma l-alpha-Acetylmethadol (LAAM) after acute and chronic administration.

Authors:  G L Henderson; B K Wilson; D H Lau
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

10.  Methadone-related deaths in Hennepin County, Minnesota: 1992-2002.

Authors:  Angelique Gagajewski; Fred S Apple
Journal:  J Forensic Sci       Date:  2003-05       Impact factor: 1.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.